Irisin as a novel biomarker of subclinical atherosclerosis, cardiovascular risk and severe disease in axial spondyloarthritis

HIGHLIGHTS

• who: Sara Remuzgo-Martí from the University of Bari Aldo Moro, Italy have published the research: Irisin as a Novel Biomarker of Subclinical Atherosclerosis, Cardiovascular Risk and Severe Disease in Axial Spondyloarthritis, in the Journal: (JOURNAL) of 11/03/2022
• what: Taking all this into consideration, in this study the authors aimed to evaluate for the first time the role of irisin as a genetic and serological biomarker of subclinical atherosclerosis and CV risk in a large cohort of Caucasian patients with axSpA. The study has several strengths, mainly the large number of individuals . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.